title: Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.
abstract: OBJECTIVE
  To analyze prognostic factors for allogeneic bone marrow transplantation (BMT) in multiple myeloma.
  
  
  METHODS
  One hundred sixty-two reports of allogeneic matched sibling-donor transplants in multiple myeloma received by the European Group for Blood and Marrow Transplantation (EBMT) registry between 1983 and early 1993 were analyzed for prognostic factors. End points were complete remission, survival, and duration of complete remission.
  
  
  RESULTS
  Following BMT, 44% of all patients and 60% of assessable patients entered complete remission. The overall actuarial survival rate was 32% at 4 years and 28% at 7 years. The overall relapse-free survival rate of 72 patients who were in complete remission after BMT was 34% at 6 years. Favorable pretransplant prognostic factors for survival were female sex (41% at 4 years), stage I disease at diagnosis (52% at 4 years), one line of previous treatment (42% at 4 years), and being in complete remission before conditioning (64% at 3 years). The subtype immunoglobulin A (IgA) myeloma and a low beta 2-microglobulin level (< 4 g/L) also tended to have a favorable prognostic impact. The most important post-transplant prognostic factor was to enter a complete remission. Grade III to IV graft-versus-host disease (GVHD) was associated with poor survival.
  
  
  CONCLUSIONS
  Patients with a low tumor burden who respond to treatment before BMT and are transplanted after first-line therapy have the best prognosis following BMT.
authors.affiliation: European Group for Blood and Marrow Transplantation, Huddinge Hospital, Sweden.
authors.forename: G
authors.initials: G
authors.lastname: Gahrton
authors.forename: S
authors.initials: S
authors.lastname: Tura
authors.forename: P
authors.initials: P
authors.lastname: Ljungman
authors.forename: J
authors.initials: J
authors.lastname: Bladé
authors.forename: L
authors.initials: L
authors.lastname: Brandt
authors.forename: M
authors.initials: M
authors.lastname: Cavo
authors.forename: T
authors.initials: T
authors.lastname: Façon
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: A
authors.initials: A
authors.lastname: Hagenbeek
authors.forename: P
authors.initials: P
authors.lastname: Jacobs
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D016026:Bone Marrow Transplantation; D002423:Cause of Death; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D016019:Survival Analysis; D014184:Transplantation, Homologous